The report provides a detailed analysis essential for establishing a Ripasudil production plant. It encompasses all critical aspects necessary for Ripasudil production, including the cost of Ripasudil production, Ripasudil plant cost, Ripasudil production costs, and the overall Ripasudil production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Ripasudil production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Ripasudil is a pharmaceutical compound that finds important applications in the healthcare and ophthalmic industries. It is primarily utilised as a medication for the treatment of glaucoma and ocular hypertension, which are conditions linked to increased pressure inside the eye. It works by lowering the pressure inside the eye by improving the drainage of fluid through the eye’s natural pathways, which helps prevent damage to the optic nerve. It is usually available in the form of eye drops and is applied directly to the affected eye. It is widely prescribed to prevent vision loss caused by long-term glaucoma. Moreover, it is also studied for its potential role in supporting corneal healing and improving blood flow in eye tissues. It is also used in pharmaceutical research associated with developing advanced therapies for various eye-related disorders.
The primary factor that drives the market for ripasudil is its application in modern eye care treatments and ongoing ophthalmic drug development, which significantly promotes its demand in the medical sector. Its application as a medication in the treatment of glaucoma and ocular hypertension further contributes to its demand in the pharmaceutical and ophthalmic industries. Its demand in the form of eye drops among patients who do not respond well to traditional eye pressure-lowering drugs further drives its market expansion.
Its usage as a drug in treating other eye disorders involving damaged cells or poor fluid drainage also drives its demand in the medical and healthcare sectors. The growing global prevalence of age-related eye disorders and the rising awareness of early treatment options significantly contribute to its market growth. Industrial ripasudil procurement depends on factors, including the availability and cost of specialised raw materials, regulatory approvals specific to ophthalmic drugs, and the need for strict compliance with sterile production standards. Furthermore, innovations in eye drop formulation, supplier consistency, packaging advancements for extended shelf life, and efficient distribution networks play a significant role in influencing procurement strategies across regions.
Raw Material for Ripasudil Production
According to the Ripasudil production plant project report, the major raw materials for Ripasudil production include (S)-2-amino-1-propanol, 2-nitrobenzenesulfonyl chloride, methanesulfonyl chloride, 3-aminopropanol, thiophenol, 4-fluoroisoquinoline-5-sulfonyl chloride, and hydrochloric acid.
Production Process of Ripasudil
The extensive Ripasudil production cost report consists of the following industrial production process:
- Production via Chemical Synthesis: The production process of ripasudil hydrochloride dihydrate begins with the protection of (S)-2-amino-1-propanol using 2-nitrobenzenesulfonyl chloride to prevent overreaction. Then, the alcohol group is activated with methanesulfonyl chloride, followed by substitution with 3-aminopropanol and protection of the resulting amine as a Boc-carbamate, which forms a main acyclic precursor. This intermediate undergoes intramolecular cyclisation using Fukuyama-Mitsunobu conditions to form the diazepane ring, after which the nosyl group is removed with thiophenol. The resulting Boc-protected diazepane is coupled with 4-fluoroisoquinoline-5-sulfonyl chloride in a one-pot reaction to form the ripasudil structure. Final deprotection with hydrochloric acid produces the ripasudil free base, followed by further acid treatment and crystallisation, which gives ripasudil hydrochloride dihydrate as the final product.
Ripasudil is a fluoroisoquinoline-based compound, and it acts as a potent and selective Rho-associated protein kinase (ROCK) inhibitor. It appears as a white to beige solid powder with a molar mass of 323.39 g/mol. The molecular formula of the compound is C15H18FN3O2S. The compound is soluble in water at approximately 2 mg/mL, highly soluble in dimethyl sulfoxide (DMSO) at about 26 mg/mL, and soluble in ethanol at approximately 5 mg/mL. It is sold under the brand name Glanatec for the treatment of glaucoma and ocular hypertension. It is commonly formulated as its hydrochloride dihydrate salt, which has the molecular formula C15H23ClFN3O4S. Common side effects associated with the compound include mild conjunctival hyperemia (eye redness), ocular irritation, and conjunctival haemorrhage. It is recommended to store the compound at 2 degree Celsius to 8 degree Celsius in a desiccated environment.
